Reviva Pharmaceuticals Holdings annual r&d spending
2019
2020
2021
2021
2022
2023
2024
2025
Reviva Pharmaceuticals Holdings R&D Spending Growth & History (RVPH)
Reviva Pharmaceuticals Holdings's r&d spending was $11.7M for fiscal 2025.
View full Reviva Pharmaceuticals Holdings company overviewReviva Pharmaceuticals Holdings annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $11.7M | −$11.2M | −48.89% |
| 2024 | 2024-12-31 | $22.9M | −$8.5M | −27.09% |
| 2023 | 2023-12-31 | $31.4M | $8.5M | +37.38% |
| 2022 | 2022-12-31 | $22.9M | — | — |
| 2021 · Dec 31 | 2021-12-31 | $4.9M | $4.6M | +1543.78% |
| 2021 · Dec 13 | 2021-12-13 | $4.9M | $4.6M | +1543.78% |
| 2020 · Dec 31 | 2020-12-31 | $295,150 | $99,406 | +50.78% |
| 2019 · Dec 31 | 2019-12-31 | $195,744 | — | — |
Reviva Pharmaceuticals Holdings quarterly r&d spending
Q1.20
Q1.21
Q2.21
Q1.21
Q2.21
Q3.21
Q4.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.4M | −$2.3M | −62.56% |
| Q1 2026 | 2026-03-31 | $1.4M | −$2.7M | −65.11% |
| Q4 2025 | 2025-12-31 | $1.7M | −$2.9M | −62.85% |
| Q3 2025 | 2025-09-30 | $2.1M | −$4.7M | −68.92% |
| Q2 2025 | 2025-06-30 | $3.7M | −$1.9M | −33.30% |
| Q1 2025 | 2025-03-31 | $4.1M | −$1.7M | −28.88% |
| Q4 2024 | 2024-12-31 | $4.7M | −$3.4M | −42.26% |
| Q3 2024 | 2024-09-30 | $6.9M | −$2.7M | −28.35% |
| Q2 2024 | 2024-06-30 | $5.6M | −$2.7M | −32.36% |
| Q1 2024 | 2024-03-31 | $5.8M | $299,720 | +5.47% |
| Q4 2023 | 2023-12-31 | $8.1M | −$177,518 | −2.14% |
| Q3 2023 | 2023-09-30 | $9.6M | $5.3M | +125.71% |
| Q2 2023 | 2023-06-30 | $8.3M | $3.7M | +82.89% |
| Q1 2023 | 2023-03-31 | $5.5M | −$345,873 | −5.93% |
| Q4 2022 | 2022-12-31 | $8.3M | — | — |
| Q3 2022 | 2022-09-30 | $4.2M | $2.8M | +197.95% |
| Q2 2022 | 2022-06-30 | $4.5M | $4.1M | +1105.99% |
| Q1 2022 | 2022-03-31 | $5.8M | $5.4M | +1390.44% |
| Q4 2021 | 2021-12-31 | $2.7M | — | — |
| Q4 2021 | 2021-12-13 | $2.7M | — | — |
| Q3 2021 · Sep 30 | 2021-09-30 | $1.4M | $1.4M | +148942.83% |
| Q2 2021 · Jun 30 | 2021-06-30 | $374,329 | $337,858 | +926.37% |
| Q1 2021 · Mar 31 | 2021-03-31 | $391,161 | $119,915 | +44.21% |
| Q2 2021 · Sep 30 | 2020-09-30 | $955 | — | — |
| Q1 2021 · Jun 30 | 2020-06-30 | $36,471 | — | — |
| Q1 2020 · Mar 31 | 2020-03-31 | $271,246 | — | — |
Reviva Pharmaceuticals Holdings r&d spending trends
Over the last five fiscal years, Reviva Pharmaceuticals Holdings's r&d spending increased from $295,150 to $11.7M, a change of $11.4M. The latest reported quarter, Q2 2026, shows $1.4M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Reviva Pharmaceuticals Holdings source filings ↗